Nevada PEBP Q1 FY24 Report 7/1/2023 – 12/31/2023

Report Includes:

- CDHP Comparison Data from Q2 FY23 to Q2 FY24
- EPO Comparison Data from Q2 FY23 to Q2 FY24
- PPO Comparison Data from Q2 FY23 to Q2 FY24
- CDHP, EPO, PPO Breakout Data from Q2 FY23 to Q2 FY24
- Summary Comparison Data from Q2 FY24
- Key Metric Breakout Data from Q2 FY24

The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.

PREPARED BY CLIENT ANALYTICS

Cynthia Eaton (Cynthia.eaton@express-scripts.com) 3/15/24





PRESCRIPTION DRUG UTILIZATION + TOTAL PLAN

+ Q2 FY24 vs Q2 FY23



| Membership Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------|------------|------------|--------|
| Member Count (Membership) | 48,640 | 48,466 | 0.4% |
| Utilizing Member Count (Patients) | 31,239 | 32,695 | -4.5% |
| Percent Utilizing (Utilization) | 64.2% | 67.5% | -3.2 |

| Claim Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------------------------|------------|------------|--------|
| Net Claims (Total Adjusted Rx's) | 369,061 | 363,725 | 1.5% |
| Claims per Elig Member per Month (Claims PMPM) | 1.26 | 1.25 | 1.1% |
| Total Claims for Generic (Generic ARx) | 314,255 | 306,021 | 2.7% |
| Total Claims for Brand (Brand ARx) | 54,806 | 57,704 | -5.0% |
| Total Claims for Multisource Brand Claims (MSB ARx) | 1,990 | 1,601 | 24.3% |
| Total Non-Specialty Claims | 364,670 | 359,974 | 1.3% |
| Total Specialty Claims | 4,391 | 3,751 | 17.1% |
| Generic % of Total Claims (GFR) | 85.1% | 84.1% | 1.0 |
| Generic Effective Rate (GCR) | 99.4% | 99.5% | -0.1 |
| Mail Order Claims | 104,196 | 99,313 | 4.9% |
| Mail Penetration Rate* | 32.4% | 31.7% | 0.7 |

| Claims Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-------------------------------------------------------------|--------------|--------------|--------|
| Total Prescription Cost (Total Gross Cost) | \$51,174,997 | \$43,163,579 | 18.6% |
| Total Generic Gross Cost | \$5,362,401 | \$5,352,108 | 0.2% |
| Total Brand Gross Cost | \$45,812,596 | \$37,811,471 | 21.2% |
| Total MSB Gross Cost | \$921,665 | \$867,609 | 6.2% |
| Total Ingredient Cost | \$49,458,504 | \$41,589,334 | 18.9% |
| Total Dispensing Fee | \$1,678,445 | \$1,527,949 | 9.8% |
| Total Other (e.g. tax) | \$38,049 | \$46,296 | -17.8% |
| Avg Total Cost per Claim (Gross Cost/ARx) | \$138.66 | \$118.67 | 16.8% |
| Avg Total Cost for Generic (Generic Gross Cost/Generic ARx) | \$17.06 | \$17.49 | -2.4% |
| Avg Total Cost for Brand (Brand Gross Cost/Brand ARx) | \$835.90 | \$655.27 | 27.6% |
| Avg Total Cost for MSB (MSB Gross Cost/MSB ARx) | \$463.15 | \$541.92 | -14.5% |



PRESCRIPTION DRUG UTILIZATION + TOTAL PLAN + Q2 FY24 vs Q2 FY23



| Member Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|---------------------------------------------------------------|-----------------------------|--------------|-----------|
| Total Member Cost Share | \$8,829,619 | \$8,353,392 | 5.7% |
| Generic Cost Share | \$2,183,710 | \$2,202,344 | -0.8% |
| Brand Cost Share | \$6,645,909 | \$6,151,048 | 8.0% |
| MSB Cost Share | \$121,078 | \$166,702 | -27.4% |
| Total Copay | \$7,681,515 | \$6,966,342 | 10.3% |
| Total Deductible | \$1,148,104 | \$1,387,050 | -17.2% |
| Avg Copay per Claim (Member Cost Share/ARx) | \$23.92 | \$22.97 | 4.2% |
| Avg Copay for Generic (Generic Member Cost Share/Generic ARx) | \$6.95 | \$7.20 | -3.4% |
| Avg Copay for Brand (Brand Member Cost Share/Brand ARx) | \$121.26 | \$106.60 | 13.8% |
| Avg Copay for MSB (MSB Member Cost Share/MSB ARx) | \$60.84 | \$104.12 | -41.6% |
| Copay % of Total Prescription Cost (Member Cost Share %) | 17.3% | 19.4% | -2.1 |
| Plan Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
| Total Plan Cost (Plan Cost) | \$42,345,378 | \$34,810,187 | 21.6% |
| Generic Plan Cost | \$3,178,691 | \$3,149,764 | 0.9% |
| Brand Plan Cost | \$39,166,687 | \$31,660,423 | 23.7% |
| MSB Plan Cost | \$800,588 | \$700,907 | 14.2% |
| Total Non-Specialty Cost (Non-Specialty Plan Cost) | \$19,758,899 | \$16,686,030 | 18.4% |
| Total Specialty Drug Cost (Specialty Plan Cost) | \$22,586,479 | \$18,124,157 | 24.6% |
| Avg Plan Cost per Claim (Plan Cost/ARx) | \$114.74 | \$95.70 | 19.9% |
| Avg Plan Cost for Generic (Generic Plan Cost/Generic ARx) | \$10.12 | \$10.29 | -1.7% |
| Avg Plan Cost for Brand (Brand Plan Cost/Brand ARx) | \$714.64 | \$548.67 | 30.3% |
| Avg Plan Cost for MSB (MSB Plan Cost/MSB ARx) | \$402.31 | \$437.79 | -8.1% |
| Avg Non-Specialty Plan Cost per Claim (Plan Cost/ARx) | \$54.18 | \$46.35 | 16.9% |
| Avg Specialty Plan Cost per Claim (Plan Cost/ARx) | \$5,143.81 | \$4,831.82 | 6.5% |
| Plan Cost PMPM | \$145.10 | \$119.71 | 21.2% |
| Non-Specialty Plan Cost PMPM | \$67.70 | \$57.38 | 18.0% |
| Specialty Plan Cost PMPM | \$77.39 | \$62.33 | 24.2% |
| Specialty % of Plan Cost | 53.3% | 52.1% | 1.3 |
| Net Plan Cost PMPM (factoring Rebates) | \$94.84 | \$83.18 | 14.0% |
| Non-Specialty Plan Cost PMPM | \$42.82 | \$36.85 | 16.2% |
| Specialty Plan Cost PMPM | \$52.02 | \$46.34 | 12.3% |
| © 2023 Exp | ress Scripts. All Rights Re | eserved. | 3/15/2024 |



PRESCRIPTION DRUG UTILIZATION

+ CDHP PLAN + Q2 FY24 vs Q2 FY23



| Membership Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------|------------|------------|--------|
| Member Count (Membership) | 24,297 | 28,010 | -13.3% |
| Utilizing Member Count (Patients) | 14,819 | 18,093 | -18.1% |
| Percent Utilizing (Utilization) | 61.0% | 64.6% | -3.6 |

| Claim Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------------------------|------------|------------|--------|
| Net Claims (Total Adjusted Rx's) | 170,990 | 193,821 | -11.8% |
| Claims per Elig Member per Month (Claims PMPM) | 1.17 | 1.15 | 1.7% |
| Total Claims for Generic (Generic ARx) | 147,083 | 163,868 | -10.2% |
| Total Claims for Brand (Brand ARx) | 23,907 | 29,953 | -20.2% |
| Total Claims for Multisource Brand Claims (MSB ARx) | 754 | 769 | -2.0% |
| Total Non-Specialty Claims | 169,049 | 191,901 | -11.9% |
| Total Specialty Claims | 1,941 | 1,920 | 1.1% |
| Generic % of Total Claims (GFR) | 86.0% | 84.5% | 1.5 |
| Generic Effective Rate (GCR) | 99.5% | 99.5% | (0.0) |
| Mail Order Claims | 46,573 | 51,531 | -9.6% |
| Mail Penetration Rate* | 31.4% | 31.0% | 0.3 |

| Claims Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-------------------------------------------------------------|--------------|--------------|--------|
| Total Prescription Cost (Total Gross Cost) | \$21,492,348 | \$21,461,228 | 0.1% |
| Total Generic Gross Cost | \$2,170,769 | \$2,594,347 | -16.3% |
| Total Brand Gross Cost | \$19,321,579 | \$18,866,881 | 2.4% |
| Total MSB Gross Cost | \$322,777 | \$447,412 | -27.9% |
| Total Ingredient Cost | \$20,692,082 | \$20,621,615 | 0.3% |
| Total Dispensing Fee | \$786,385 | \$818,293 | -3.9% |
| Total Other (e.g. tax) | \$13,880 | \$21,320 | -34.9% |
| Avg Total Cost per Claim (Gross Cost/ARx) | \$125.69 | \$110.73 | 13.5% |
| Avg Total Cost for Generic (Generic Gross Cost/Generic ARx) | \$14.76 | \$15.83 | -6.8% |
| Avg Total Cost for Brand (Brand Gross Cost/Brand ARx) | \$808.20 | \$629.88 | 28.3% |
| Avg Total Cost for MSB (MSB Gross Cost/MSB ARx) | \$428.09 | \$581.81 | -26.4% |

4



PRESCRIPTION DRUG UTILIZATION

+ CDHP PLAN + Q2 FY24 vs Q2 FY23



| Member Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-------------------------------------------------------------|--------------------------------|--------------|-----------|
| Total Member Cost Share | \$4,776,329 | \$5,074,756 | -5.9% |
| Generic Cost Share | \$1,054,669 | \$1,252,187 | -15.8% |
| Brand Cost Share | \$3,721,660 | \$3,822,569 | -2.6% |
| MSB Cost Share | \$74,141 | \$134,559 | -44.9% |
| Total Copay | \$3,630,113 | \$3,689,916 | -1.6% |
| Total Deductible | \$1,146,216 | \$1,384,840 | -17.2% |
| Avg Copay per Claim (Member Cost Share/ARx) | \$27.93 | \$26.18 | 6.7% |
| Avg Copay for Generic (Generic Member Cost Share/Generic AF | Rx) \$7.17 | \$7.64 | -6.2% |
| Avg Copay for Brand (Brand Member Cost Share/Brand ARx) | \$155.67 | \$127.62 | 22.0% |
| Avg Copay for MSB (MSB Member Cost Share/MSB ARx) | \$98.33 | \$174.98 | -43.8% |
| Copay % of Total Prescription Cost (Member Cost Share %) | 22.2% | 23.6% | -1.4 |
| Plan Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
| Total Plan Cost (Plan Cost) | \$16,716,019 | \$16,386,472 | 2.0% |
| Generic Plan Cost | \$1,116,100 | \$1,342,160 | -16.8% |
| Brand Plan Cost | \$15,599,919 | \$15,044,312 | 3.7% |
| MSB Plan Cost | \$248,636 | \$312,853 | -20.5% |
| Total Non-Specialty Cost (Non-Specialty Plan Cost) | \$6,877,440 | \$6,997,252 | -1.7% |
| Total Specialty Drug Cost (Specialty Plan Cost) | \$9,838,579 | \$9,389,220 | 4.8% |
| Avg Plan Cost per Claim (Plan Cost/ARx) | \$97.76 | \$84.54 | 15.6% |
| Avg Plan Cost for Generic (Generic Plan Cost/Generic ARx) | \$7.59 | \$8.19 | -7.4% |
| Avg Plan Cost for Brand (Brand Plan Cost/Brand ARx) | \$652.53 | \$502.26 | 29.9% |
| Avg Plan Cost for MSB (MSB Plan Cost/MSB ARx) | \$329.76 | \$406.83 | -18.9% |
| Avg Non-Specialty Plan Cost per Claim (Plan Cost/ARx) | \$40.68 | \$36.46 | 11.6% |
| Avg Specialty Plan Cost per Claim (Plan Cost/ARx) | \$5,068.82 | \$4,890.22 | 3.7% |
| Plan Cost PMPM | \$114.66 | \$97.50 | 17.6% |
| Non-Specialty Plan Cost PMPM | \$47.18 | \$41.64 | 13.3% |
| Specialty Plan Cost PMPM | \$67.49 | \$55.87 | 20.8% |
| Specialty % of Plan Cost | 58.9% | 57.3% | 1.6 |
| Net Plan Cost PMPM (factoring Rebates) | \$73.39 | \$67.29 | 9.1% |
| Non-Specialty Plan Cost PMPM | \$27.76 | \$25.16 | 10.3% |
| Specialty Plan Cost PMPM | \$45.63 | \$42.13 | 8.3% |
| © 2023 | Express Scripts. All Rights Re | eserved. | 3/15/2024 |

5



PRESCRIPTION DRUG UTILIZATION + EPO PLAN + Q2 FY24 vs Q2 FY23



| Membership Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------|------------|------------|--------|
| Member Count (Membership) | 5,797 | 6,559 | -11.6% |
| Utilizing Member Count (Patients) | 4,161 | 4,948 | -15.9% |
| Percent Utilizing (Utilization) | 71.8% | 75.4% | -3.7 |

| Claim Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------------------------|------------|------------|--------|
| Net Claims (Total Adjusted Rx's) | 63,291 | 69,558 | -9.0% |
| Claims per Elig Member per Month (Claims PMPM) | 1.82 | 1.77 | 3.0% |
| Total Claims for Generic (Generic ARx) | 53,768 | 58,812 | -8.6% |
| Total Claims for Brand (Brand ARx) | 9,523 | 10,746 | -11.4% |
| Total Claims for Multisource Brand Claims (MSB ARx) | 413 | 326 | 26.7% |
| Total Non-Specialty Claims | 62,523 | 68,700 | -9.0% |
| Total Specialty Claims | 768 | 858 | -10.5% |
| Generic % of Total Claims (GFR) | 85.0% | 84.6% | 0.4 |
| Generic Effective Rate (GCR) | 99.2% | 99.4% | -0.2 |
| Mail Order Claims | 18,689 | 18,173 | 2.8% |
| Mail Penetration Rate* | 32.7% | 29.3% | 3.4 |

| Claims Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-------------------------------------------------------------|--------------|-------------|--------|
| Total Prescription Cost (Total Gross Cost) | \$10,045,058 | \$9,846,897 | 2.0% |
| Total Generic Gross Cost | \$933,816 | \$1,092,103 | -14.5% |
| Total Brand Gross Cost | \$9,111,242 | \$8,754,795 | 4.1% |
| Total MSB Gross Cost | \$223,146 | \$193,921 | 15.1% |
| Total Ingredient Cost | \$9,763,024 | \$9,559,049 | 2.1% |
| Total Dispensing Fee | \$273,452 | \$279,289 | -2.1% |
| Total Other (e.g. tax) | \$8,581 | \$8,559 | 0.3% |
| Avg Total Cost per Claim (Gross Cost/ARx) | \$158.71 | \$141.56 | 12.1% |
| Avg Total Cost for Generic (Generic Gross Cost/Generic ARx) | \$17.37 | \$18.57 | -6.5% |
| Avg Total Cost for Brand (Brand Gross Cost/Brand ARx) | \$956.76 | \$814.70 | 17.4% |
| Avg Total Cost for MSB (MSB Gross Cost/MSB ARx) | \$540.31 | \$594.85 | -9.2% |

© 2023 Express Scripts. All Rights Reserved.

6



PRESCRIPTION DRUG UTILIZATION + EPO PLAN + Q2 FY24 vs Q2 FY23



| Member Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|---------------------------------------------------------------|-------------|-------------|--------|
| Total Member Cost Share | \$1,331,951 | \$1,470,033 | -9.4% |
| Generic Cost Share | \$367,712 | \$399,198 | -7.9% |
| Brand Cost Share | \$964,238 | \$1,070,834 | -10.0% |
| MSB Cost Share | \$21,734 | \$24,589 | -11.6% |
| Total Copay | \$1,330,062 | \$1,467,823 | -9.4% |
| Total Deductible | \$1,889 | \$2,210 | -14.5% |
| Avg Copay per Claim (Member Cost Share/ARx) | \$21.04 | \$21.13 | -0.4% |
| Avg Copay for Generic (Generic Member Cost Share/Generic ARx) | \$6.84 | \$6.79 | 0.8% |
| Avg Copay for Brand (Brand Member Cost Share/Brand ARx) | \$101.25 | \$99.65 | 1.6% |
| Avg Copay for MSB (MSB Member Cost Share/MSB ARx) | \$52.63 | \$75.43 | -30.2% |
| Copay % of Total Prescription Cost (Member Cost Share %) | 13.3% | 14.9% | -1.7 |
| Plan Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
| Total Plan Cost (Plan Cost) | \$8,713,107 | \$8,376,865 | 4.0% |
| Generic Plan Cost | \$566,104 | \$692,904 | -18.3% |
| Brand Plan Cost | \$8,147,004 | \$7,683,960 | 6.0% |
| MSB Plan Cost | \$201,412 | \$169,332 | 18.9% |
| Total Non-Specialty Cost (Non-Specialty Plan Cost) | \$4,140,543 | \$4,119,692 | 0.5% |
| Total Specialty Drug Cost (Specialty Plan Cost) | \$4,572,564 | \$4,257,173 | 7.4% |
| Avg Plan Cost per Claim (Plan Cost/ARx) | \$137.67 | \$120.43 | 14.3% |
| Avg Plan Cost for Generic (Generic Plan Cost/Generic ARx) | \$10.53 | \$11.78 | -10.6% |
| Avg Plan Cost for Brand (Brand Plan Cost/Brand ARx) | \$855.51 | \$715.05 | 19.6% |
| Avg Plan Cost for MSB (MSB Plan Cost/MSB ARx) | \$487.68 | \$519.42 | -6.1% |
| Avg Non-Specialty Plan Cost per Claim (Plan Cost/ARx) | \$66.22 | \$59.97 | 10.4% |
| Avg Specialty Plan Cost per Claim (Plan Cost/ARx) | \$5,953.86 | \$4,961.74 | 20.0% |
| Plan Cost PMPM | \$250.51 | \$212.86 | 17.7% |
| Non-Specialty Plan Cost PMPM | \$119.04 | \$104.68 | 13.7% |
| Specialty Plan Cost PMPM | \$131.46 | \$108.18 | 21.5% |
| Specialty % of Plan Cost | 52.5% | 50.8% | 1.7 |
| Net Plan Cost PMPM (factoring Rebates) | \$168.02 | \$149.33 | 12.5% |
| Non-Specialty Plan Cost PMPM | \$75.05 | \$68.40 | 9.7% |
| Specialty Plan Cost PMPM | \$92.97 | \$80.94 | 14.9% |

© 2023 Express Scripts. All Rights Reserved.

7



PRESCRIPTION DRUG UTILIZATION + PPO PLAN + Q2 FY24 vs Q2 FY23



| Membership Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------|------------|------------|--------|
| Member Count (Membership) | 18,549 | 13,900 | 33.4% |
| Utilizing Member Count (Patients) | 12,302 | 9,717 | 26.6% |
| Percent Utilizing (Utilization) | 66.3% | 69.9% | -3.6 |

| Claim Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-----------------------------------------------------|------------|------------|--------|
| Net Claims (Total Adjusted Rx's) | 134,780 | 100,346 | 34.3% |
| Claims per Elig Member per Month (Claims PMPM) | 1.21 | 1.20 | 0.7% |
| Total Claims for Generic (Generic ARx) | 113,404 | 83,341 | 36.1% |
| Total Claims for Brand (Brand ARx) | 21,376 | 17,005 | 25.7% |
| Total Claims for Multisource Brand Claims (MSB ARx) | 823 | 506 | 62.6% |
| Total Non-Specialty Claims | 133,098 | 99,373 | 33.9% |
| Total Specialty Claims | 1,682 | 973 | 72.9% |
| Generic % of Total Claims (GFR) | 84.1% | 83.1% | 1.1 |
| Generic Effective Rate (GCR) | 99.3% | 99.4% | -0.1 |
| Mail Order Claims | 38,934 | 29,609 | 31.5% |
| Mail Penetration Rate* | 33.5% | 34.7% | (1.2) |

| Claims Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
|-------------------------------------------------------------|--------------|--------------|--------|
| Total Prescription Cost (Total Gross Cost) | \$19,637,591 | \$11,855,454 | 65.6% |
| Total Generic Gross Cost | \$2,257,816 | \$1,665,659 | 35.6% |
| Total Brand Gross Cost | \$17,379,775 | \$10,189,795 | 70.6% |
| Total MSB Gross Cost | \$375,742 | \$226,275 | 66.1% |
| Total Ingredient Cost | \$19,003,397 | \$11,408,670 | 66.6% |
| Total Dispensing Fee | \$618,607 | \$430,366 | 43.7% |
| Total Other (e.g. tax) | \$15,587 | \$16,417 | -5.1% |
| Avg Total Cost per Claim (Gross Cost/ARx) | \$145.70 | \$118.15 | 23.3% |
| Avg Total Cost for Generic (Generic Gross Cost/Generic ARx) | \$19.91 | \$19.99 | -0.4% |
| Avg Total Cost for Brand (Brand Gross Cost/Brand ARx) | \$813.05 | \$599.22 | 35.7% |
| Avg Total Cost for MSB (MSB Gross Cost/MSB ARx) | \$456.55 | \$447.18 | 2.1% |

3/15/2024

8



PRESCRIPTION DRUG UTILIZATION + PPO PLAN + Q2 FY24 vs Q2 FY23



| | | | Fublic employees benefits Flogram |
|---------------------------------------------------------------|----------------------|--------------|-----------------------------------|
| Member Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
| Total Member Cost Share | \$2,721,339 | \$1,808,603 | 50.5% |
| Generic Cost Share | \$761,329 | \$550,958 | 38.2% |
| Brand Cost Share | \$1,960,011 | \$1,257,645 | 55.8% |
| MSB Cost Share | \$25,202 | \$7,553 | 233.7% |
| Total Copay | \$2,721,339 | \$1,808,603 | 50.5% |
| Total Deductible | \$0 | \$0 | NA |
| Avg Copay per Claim (Member Cost Share/ARx) | \$20.19 | \$18.02 | 12.0% |
| Avg Copay for Generic (Generic Member Cost Share/Generic ARx) | \$6.71 | \$6.61 | 1.6% |
| Avg Copay for Brand (Brand Member Cost Share/Brand ARx) | \$91.69 | \$73.96 | 24.0% |
| Avg Copay for MSB (MSB Member Cost Share/MSB ARx) | \$30.62 | \$14.93 | 105.1% |
| Copay % of Total Prescription Cost (Member Cost Share %) | 13.9% | 15.3% | -1.4 |
| Plan Cost Summary | Q2 FY 2024 | Q2 FY 2023 | Change |
| Total Plan Cost (Plan Cost) | \$16,916,252 | \$10,046,851 | 68.4% |
| Generic Plan Cost | \$1,496,488 | \$1,114,700 | 34.3% |
| Brand Plan Cost | \$15,419,764 | \$8,932,150 | 72.6% |
| MSB Plan Cost | \$350,540 | \$218,722 | 60.3% |
| Total Non-Specialty Cost (Non-Specialty Plan Cost) | \$8,740,916 | \$5,569,086 | 57.0% |
| Total Specialty Drug Cost (Specialty Plan Cost) | \$8,175,336 | \$4,477,765 | 82.6% |
| Avg Plan Cost per Claim (Plan Cost/ARx) | \$125.51 | \$100.12 | 25.4% |
| Avg Plan Cost for Generic (Generic Plan Cost/Generic ARx) | \$13.20 | \$13.38 | -1.3% |
| Avg Plan Cost for Brand (Brand Plan Cost/Brand ARx) | \$721.36 | \$525.27 | 37.3% |
| Avg Plan Cost for MSB (MSB Plan Cost/MSB ARx) | \$425.93 | \$432.26 | -1.5% |
| Avg Non-Specialty Plan Cost per Claim (Plan Cost/ARx) | \$65.67 | \$56.04 | 17.2% |
| Avg Specialty Plan Cost per Claim (Plan Cost/ARx) | \$4,860.49 | \$4,602.02 | 5.6% |
| Plan Cost PMPM | \$152.00 | \$120.47 | 26.2% |
| Non-Specialty Plan Cost PMPM | \$78.54 | \$66.78 | 17.6% |
| Specialty Plan Cost PMPM | \$73.46 | \$53.69 | 36.8% |
| Specialty % of Plan Cost | 48.3% | 44.6% | 3.8 |
| Net Plan Cost PMPM (factoring Rebates) | \$100.05 | \$83.98 | 19.1% |
| Non-Specialty Plan Cost PMPM | \$52.46 | \$45.50 | 15.3% |
| Specialty Plan Cost PMPM | \$47.59 | \$38.48 | 23.7% |
| © 2022 Everes | Societo All Diabto D | a convoid | |



PRESCRIPTION DRUG UTILIZATION + EPO, CDHP, & PPO PLAN + Q2 FY24 vs Q2 FY23



| Total | EPO | CDHP | PPO |
|--------|------------------|------------------------------|------------------------------------|
| 48,640 | 5,797 | 24,297 | 18,549 |
| 31,239 | 4,161 | 14,819 | 12,302 |
| 64.2% | 71.8% | 61.0% | 66.3% |
| | 48,640 31,239 | 48,640 5,797 31,239 4,161 | 48,6405,79724,29731,2394,16114,819 |

| Claim Summary | Total | EPO | CDHP | PPO |
|----------------------------------------------------|--------------|--------------|--------------|--------------|
| Net Claims (Total Rx's) | 369,061 | 63,291 | 170,990 | 134,780 |
| Claims per Elig Member per Month (Claims PMPM) | 1.26 | 1.82 | 1.17 | 1.21 |
| Total Claims for Generic (Generic Rx) | 314,255 | 53,768 | 147,083 | 113,404 |
| Total Claims for Brand (Brand Rx) | 54,806 | 9,523 | 23,907 | 21,376 |
| Total Claims for Multisource Brand Claims (MSB Rx) | 1,990 | 413 | 754 | 823 |
| Total Non-Specialty Claims | 364,670 | 62,523 | 169,049 | 133,098 |
| Total Specialty Claims | 4,391 | 768 | 1,941 | 1,682 |
| Generic % of Total Claims (GFR) | 85.1% | 85.0% | 86.0% | 84.1% |
| Generic Effective Rate (GCR) | 99.4% | 99.2% | 99.5% | 99.3% |
| Mail Order Claims | 104,196 | 18,689 | 46,573 | 38,934 |
| Mail Penetration Rate* | 32.4% | 32.7% | 31.4% | 33.5% |
| Claims Cost Summary | Total | EPO | CDHP | PPO |
| Total Prescription Cost (Total Gross Cost) | \$51,174,997 | \$10,045,058 | \$21,492,348 | \$19,637,591 |
| Total Generic Gross Cost | \$5,362,401 | \$933,816 | \$2,170,769 | \$2,257,816 |
| Total Brand Gross Cost | \$45,812,596 | \$9,111,242 | \$19,321,579 | \$17,379,775 |
| Total MSB Gross Cost | \$921,665 | \$223,146 | \$322,777 | \$375,742 |
| Total Ingredient Cost | \$49,458,504 | \$9,763,024 | \$20,692,082 | \$19,003,397 |

| | i Otai | | | |
|--------------------------------------------|--------------|--------------|--------------|--------------|
| Total Prescription Cost (Total Gross Cost) | \$51,174,997 | \$10,045,058 | \$21,492,348 | \$19,637,591 |
| Total Generic Gross Cost | \$5,362,401 | \$933,816 | \$2,170,769 | \$2,257,816 |
| Total Brand Gross Cost | \$45,812,596 | \$9,111,242 | \$19,321,579 | \$17,379,775 |
| Total MSB Gross Cost | \$921,665 | \$223,146 | \$322,777 | \$375,742 |
| Total Ingredient Cost | \$49,458,504 | \$9,763,024 | \$20,692,082 | \$19,003,397 |
| Total Dispensing Fee | \$1,059,838 | \$273,452 | \$786,385 | \$618,607 |
| Total Other (e.g. tax) | \$38,049 | \$8,581 | \$13,880 | \$15,587 |
| Avg Total Cost per Claim (Gross Cost/Rx) | \$138.66 | \$158.71 | \$125.69 | \$145.70 |
| Avg Total Cost for Generic | | | | |
| (Generic Gross Cost/Generic Rx) | \$17.06 | \$17.37 | \$14.76 | \$19.91 |
| Avg Total Cost for Brand | | | | |
| (Brand Gross Cost/Brand Rx) | \$835.90 | \$956.76 | \$808.20 | \$813.05 |
| Avg Total Cost for MSB | | | | |
| (MSB Gross Cost/MSB Rx) | \$463.15 | \$540.31 | \$428.09 | \$456.55 |



11

STATE OF NEVADA PEBP:

PRESCRIPTION DRUG UTILIZATION + EPO, CDHP, & PPO PLAN + Q2 FY24 vs Q2 FY23



| Member Cost Summary | Total | EPO | CDHP | PPO |
|----------------------------------------------------------|-------------|-------------|-------------|-------------|
| Total Member Cost Share | \$8,829,619 | \$1,331,951 | \$4,776,329 | \$2,721,339 |
| Generic Cost Share | \$2,183,710 | \$367,712 | \$1,054,669 | \$761,329 |
| Brand Cost Share | \$6,645,909 | \$964,238 | \$3,721,660 | \$1,960,011 |
| MSB Cost Share | \$121,078 | \$21,734 | \$74,141 | \$25,202 |
| Total Copay | \$7,681,515 | \$1,330,062 | \$3,630,113 | \$2,721,339 |
| Total Deductible | \$1,148,104 | \$1,889 | \$1,146,216 | \$0 |
| Avg Copay per Claim (Member Cost Share/Rx) | \$23.92 | \$21.04 | \$27.93 | \$20.19 |
| Avg Copay for Generic | | | | |
| (Generic Member Cost Share/Generic Rx) | \$6.95 | \$6.84 | \$7.17 | \$6.71 |
| Avg Copay for Brand | | | | |
| (Brand Member Cost Share/Brand Rx) | \$121.26 | \$101.25 | \$155.67 | \$91.69 |
| Avg Copay for MSB | | | | |
| (MSB Member Cost Share/MSB Rx) | \$60.84 | \$52.63 | \$98.33 | \$30.62 |
| Copay % of Total Prescription Cost (Member Cost Share %) | 17.3% | 13.3% | 22.2% | 13.9% |

| Plan Cost Summary | Total | EPO | CDHP | PPO |
|----------------------------------------------------------|-------------------------|------------------|--------------|--------------|
| Total Plan Cost (Plan Cost) | \$42,345,378 | \$8,713,107 | \$16,716,019 | \$16,916,252 |
| Generic Plan Cost | \$3,178,691 | \$566,104 | \$1,116,100 | \$1,496,488 |
| Brand Plan Cost | \$39,166,687 | \$8,147,004 | \$15,599,919 | \$15,419,764 |
| MSB Plan Cost | \$800,588 | \$201,412 | \$248,636 | \$350,540 |
| Total Non-Specialty Cost (Non-Specialty Plan Cost) | \$19,758,899 | \$4,140,543 | \$6,877,440 | \$8,740,916 |
| Total Specialty Drug Cost (Specialty Plan Cost) | \$22,586,479 | \$4,572,564 | \$9,838,579 | \$8,175,336 |
| Avg Plan Cost per Claim (Plan Cost/Rx) | \$114.74 | \$137.67 | \$97.76 | \$125.51 |
| Avg Plan Cost for Generic (Generic Plan Cost/Generic Rx) | \$10.12 | \$10.53 | \$7.59 | \$13.20 |
| Avg Plan Cost for Brand (Brand Plan Cost/Brand Rx) | \$714.64 | \$855.51 | \$652.53 | \$721.36 |
| Avg Plan Cost for MSB (MSB Plan Cost/MSB Rx) | \$402.31 | \$487.68 | \$329.76 | \$425.93 |
| Avg Non-Specialty Plan Cost per Claim (Plan Cost/Rx) | \$54.18 | \$66.22 | \$40.68 | \$65.67 |
| Avg Specialty Plan Cost per Claim (Plan Cost/Rx) | \$5,143.81 | \$5,953.86 | \$5,068.82 | \$4,860.49 |
| Plan Cost PMPM | \$145.10 | \$250.51 | \$114.66 | \$152.00 |
| Non-Specialty Plan Cost PMPM | \$67.70 | \$119.04 | \$47.18 | \$78.54 |
| Specialty Plan Cost PMPM | \$77.39 | \$131.46 | \$67.49 | \$73.46 |
| Specialty % of Plan Cost | 53.3% | 52.5% | 58.9% | 48.3% |
| Net Plan Cost PMPM (factoring Rebates) | \$94.84 | \$168.02 | \$73.39 | \$100.05 |
| Non-Specialty Net Plan Cost PMPM | \$42.82 | \$75.05 | \$27.76 | \$52.46 |
| Specialty Net Plan Cost PMPM | \$52.02 | \$92.97 | \$45.63 | \$47.59 |
| | © 2023 Express Scripts. | All Rights Reser | rved. | 3/15/2024 1 |



| PRESCRIPTION |
|----------------------|
| DRUG UTILIZATION |
| + TOTAL PLAN |
| + Q2 FY24 vs Q2 FY23 |

| State of Nevada PEBP | | | | | | | | |
|--------------------------------|--------------------------------|--------------|---------------|---------------|--|--|--|--|
| Q2 FY2024 - FY2024 | | | | | | | | |
| Description | scription Grand Total EPO CDHP | | | | | | | |
| Avg Members per Month | 48,640 | 5,797 | 24,297 | 18,549 | | | | |
| Pct Members Utilizing Benefit | 64.2% | 71.8% | 61.0% | 66.3% | | | | |
| Total Plan Cost | \$ 42,345,378 | \$ 8,713,107 | \$ 16,716,019 | \$ 16,916,252 | | | | |
| Total Days | 9,531,769 | 1,691,004 | 4,404,292 | 3,436,473 | | | | |
| Total Adjusted Rxs | 369,061 | 63,291 | 170,990 | 134,780 | | | | |
| Plan Cost PMPM | \$ 145.10 | \$ 250.51 | \$ 114.66 | \$ 152.00 | | | | |
| Plan Cost Net PMPM | \$ 94.84 | \$ 168.02 | \$ 73.39 | \$ 100.05 | | | | |
| Plan Cost/Day | \$ 4.44 | \$ 5.15 | \$ 3.80 | \$ 4.92 | | | | |
| Plan Cost per Adjusted Rx | \$ 114.74 | \$ 137.67 | \$ 97.76 | \$ 125.51 | | | | |
| Nbr Rxs PMPM | 1.26 | 1.82 | 1.17 | 1.21 | | | | |
| Generic Fill Rate | 85.1% | 85.0% | 86.0% | 84.1% | | | | |
| Home Delivery Utilization | 32.4% | 32.7% | 31.4% | 33.5% | | | | |
| Member Cost % | 17.3% | 13.3% | 22.2% | 13.9% | | | | |
| Specialty Percent of Plan Cost | 53.3% | 52.5% | 58.9% | 48.3% | | | | |
| Specialty Plan Cost PMPM | \$ 77.39 | \$ 131.46 | \$ 67.49 | \$ 73.46 | | | | |
| Formulary Compliance Rate | 99.4% | 99.3% | 99.6% | 99.2% | | | | |





PRESCRIPTION DRUG UTILIZATION + TOTAL PLAN + Q2 FY24 vs Q2 FY23

| State of Nevada PEBP | | | | | | | | |
|--------------------------------|---------------|---------------|----------------|---------------------|--------------------|--|--|--|
| Q2 FY2024 - Grand Total | | | | | | | | |
| Description | Grand Total | State Actives | State Retirees | Non-State Actives N | Ion-State Retirees | | | |
| Avg Members per Month | 48,640 | 42,383 | 5,744 | 12 | 503 | | | |
| Pct Members Utilizing Benefit | 64.2% | 62.2% | 78.3% | 58.3% | 90.9% | | | |
| Total Plan Cost | \$ 42,345,378 | \$ 33,238,455 | \$ 7,940,993 | \$ 217,391 | \$ 948,539 | | | |
| Total Days | 9,531,769 | 7,084,152 | 2,134,154 | 4,423 | 309,040 | | | |
| Total Adjusted Rxs | 369,061 | 278,745 | 78,899 | 166 | 11,251 | | | |
| Plan Cost PMPM | \$ 145.10 | \$ 130.71 | \$ 230.41 | \$ 3,019.32 | \$ 314.29 | | | |
| Plan Cost Net PMPM | \$ 94.84 | \$ 86.15 | \$ 146.03 | \$ 2,709.79 | \$ 179.24 | | | |
| Plan Cost/Day | \$ 4.44 | \$ 4.69 | \$ 3.72 | \$ 49.15 | \$ 3.07 | | | |
| Plan Cost per Adjusted Rx | \$ 114.74 | \$ 119.24 | \$ 100.65 | \$ 1,309.58 | \$ 84.31 | | | |
| Nbr Rxs PMPM | 1.26 | 1.10 | 2.29 | 2.31 | 3.73 | | | |
| Generic Fill Rate | 85.1% | 84.7% | 86.4% | 84.3% | 86.7% | | | |
| Home Delivery Utilization | 32.4% | 30.1% | 39.1% | 93.3% | 37.0% | | | |
| Member Cost % | 17.3% | 16.8% | 19.1% | 20.3% | 18.3% | | | |
| Specialty Percent of Plan Cost | 53.3% | 53.9% | 51.1% | 96.4% | 42.1% | | | |
| Specialty Plan Cost PMPM | \$ 77.39 | \$ 70.46 | \$ 117.81 | \$ 2,911.50 | \$ 132.33 | | | |
| Formulary Compliance Rate | 99.4% | 99.4% | 99.5% | 100.0% | 99.5% | | | |





PRESCRIPTION DRUG UTILIZATION

+ CDHP PLAN + Q2 FY24 vs Q2 FY23

| State of Nevada PEBP | | | | | | | | |
|--------------------------------|---------------|---------------|----------------|-------------------|--------------------|--|--|--|
| Q2 FY2024 - CDHP | | | | | | | | |
| Description | CDHP | State Actives | State Retirees | Non-State Actives | Non-State Retirees | | | |
| Avg Members per Month | 24,297 | 20,228 | 3,679 | 8 | 383 | | | |
| Pct Members Utilizing Benefit | 61.0% | 58.0% | 75.6% | 50.0% | 91.1% | | | |
| Total Plan Cost | \$ 16,716,019 | \$ 11,619,979 | \$ 4,311,558 | \$ 131,901 | \$ 652,581 | | | |
| Total Days | 4,404,292 | 2,896,810 | 1,264,866 | 1,412 | 241,204 | | | |
| Total Adjusted Rxs | 170,990 | 115,342 | 46,803 | 55 | 8,790 | | | |
| Plan Cost PMPM | \$ 114.66 | \$ 95.74 | \$ 195.32 | \$ 2,747.94 | \$ 283.98 | | | |
| Plan Cost Net PMPM | \$ 73.39 | \$ 61.34 | \$ 126.50 | \$ 2,616.93 | \$ 146.10 | | | |
| Plan Cost/Day | \$ 3.80 | \$ 4.01 | \$ 3.41 | \$ 93.41 | \$ 2.71 | | | |
| Plan Cost per Adjusted Rx | \$ 97.76 | \$ 100.74 | \$ 92.12 | \$ 2,398.21 | \$ 74.24 | | | |
| Nbr Rxs PMPM | 1.17 | 0.95 | 2.12 | 1.15 | 3.83 | | | |
| Generic Fill Rate | 86.0% | 85.5% | 87.3% | 85.5% | 86.1% | | | |
| Home Delivery Utilization | 31.4% | 27.7% | 38.3% | 95.9% | 37.6% | | | |
| Member Cost % | 22.2% | 22.6% | 21.3% | 25.7% | 19.9% | | | |
| Specialty Percent of Plan Cost | 58.9% | 59.5% | 59.4% | 99.7% | 36.3% | | | |
| Specialty Plan Cost PMPM | \$ 67.49 | \$ 56.94 | \$ 115.97 | \$ 2,739.69 | \$ 103.07 | | | |
| Formulary Compliance Rate | 99.6% | 99.6% | 99.6% | 100.0% | 99.6% | | | |





PRESCRIPTION DRUG UTILIZATION + EPO PLAN + Q2 FY24 vs Q2 FY23

| State of Nevada PEBP | | | | | | | | | |
|--------------------------------|--------------|---------------|----------------|---------------------|--------------------|--|--|--|--|
| Q2 FY2024 - EPO | | | | | | | | | |
| Description | EPO | State Actives | State Retirees | Non-State Actives N | Ion-State Retirees | | | | |
| Avg Members per Month | 5,797 | 5,021 | 698 | 2 | 76 | | | | |
| Pct Members Utilizing Benefit | 71.8% | 69.8% | 87.5% | 50.0% | 85.5% | | | | |
| Total Plan Cost | \$ 8,713,107 | \$ 6,824,521 | \$ 1,735,305 | \$ 6,150 | \$ 147,131 | | | | |
| Total Days | 1,691,004 | 1,284,263 | 363,960 | 1,710 | 41,071 | | | | |
| Total Adjusted Rxs | 63,291 | 48,488 | 13,265 | 57 | 1,481 | | | | |
| Plan Cost PMPM | \$ 250.51 | \$ 226.53 | \$ 414.35 | \$ 615.02 | \$ 322.66 | | | | |
| Plan Cost Net PMPM | \$ 168.02 | \$ 151.73 | \$ 278.90 | \$ 273.08 | \$ 224.13 | | | | |
| Plan Cost/Day | \$ 5.15 | \$ 5.31 | \$ 4.77 | \$ 3.60 | \$ 3.58 | | | | |
| Plan Cost per Adjusted Rx | \$ 137.67 | \$ 140.75 | \$ 130.82 | \$ 107.90 | \$ 99.35 | | | | |
| Nbr Rxs PMPM | 1.82 | 1.61 | 3.17 | 4.75 | 3.73 | | | | |
| Generic Fill Rate | 85.0% | 84.7% | 85.5% | 78.9% | 88.6% | | | | |
| Home Delivery Utilization | 32.7% | 31.9% | 34.7% | 100.0% | 36.7% | | | | |
| Member Cost % | 13.3% | 12.2% | 16.7% | 8.5% | 17.7% | | | | |
| Specialty Percent of Plan Cost | 52.5% | 53.8% | 47.6% | 0.0% | 50.3% | | | | |
| Specialty Plan Cost PMPM | \$ 131.46 | \$ 121.90 | \$ 197.32 | \$ - | \$ 162.19 | | | | |
| Formulary Compliance Rate | 99.3% | 99.2% | 99.5% | 100.0% | 98.8% | | | | |





PRESCRIPTION DRUG UTILIZATION + PPO PLAN + Q2 FY24 vs Q2 FY23

| State of Nevada PEBP | | | | | | | | | |
|--------------------------------|---------------|---------------|----------------|---------------------|--------------------|--|--|--|--|
| Q2 FY2024 - PPO | | | | | | | | | |
| Description | PPO | State Actives | State Retirees | Non-State Actives N | Ion-State Retirees | | | | |
| Avg Members per Month | 18,549 | 17,135 | 1,367 | 2 | 44 | | | | |
| Pct Members Utilizing Benefit | 66.3% | 65.2% | 81.3% | 100.0% | 97.7% | | | | |
| Total Plan Cost | \$ 16,916,252 | \$ 14,793,955 | \$ 1,894,130 | \$ 79,339 | \$ 148,827 | | | | |
| Total Days | 3,436,473 | 2,903,079 | 505,328 | 1,301 | 26,765 | | | | |
| Total Adjusted Rxs | 134,780 | 114,915 | 18,831 | 54 | 980 | | | | |
| Plan Cost PMPM | \$ 152.00 | \$ 143.90 | \$ 230.94 | \$ 6,611.62 | \$ 563.74 | | | | |
| Plan Cost Net PMPM | \$ 100.05 | \$ 96.22 | \$ 130.76 | \$ 5,563.49 | \$ 390.18 | | | | |
| Plan Cost/Day | \$ 4.92 | \$ 5.10 | \$ 3.75 | \$ 60.98 | \$ 5.56 | | | | |
| Plan Cost per Adjusted Rx | \$ 125.51 | \$ 128.74 | \$ 100.59 | \$ 1,469.25 | \$ 151.86 | | | | |
| Nbr Rxs PMPM | 1.21 | 1.12 | 2.30 | 4.50 | 3.71 | | | | |
| Generic Fill Rate | 84.1% | 84.0% | 84.8% | 88.9% | 88.9% | | | | |
| Home Delivery Utilization | 33.5% | 31.6% | 44.3% | 81.8% | 31.9% | | | | |
| Member Cost % | 13.9% | 13.7% | 15.8% | 10.3% | 11.1% | | | | |
| Specialty Percent of Plan Cost | 48.3% | 49.6% | 35.6% | 98.5% | 59.5% | | | | |
| Specialty Plan Cost PMPM | \$ 73.46 | \$ 71.34 | \$ 82.15 | \$ 6,510.23 | \$ 335.38 | | | | |
| Formulary Compliance Rate | 99.2% | 99.2% | 99.3% | 100.0% | 100.0% | | | | |

